BRAF MELANOMA
in Latin America

The discovery of BRAF mutations in half of all melanomas has unleashed the potential for molecular targeted therapies. Combined targeted treatments have shown a dramatic increase in overall survival (OS). Although ample evidence exists regarding the positive impact of targeted therapies for patients with BRAF-mutated melanoma, studies regarding the impact of target therapies on healthcare costs are scarce. In Latin America, barriers of access to advanced diagnostic tools such as molecular testing; the lack of prior region-specific genomic knowledge; and the barriers of access to target-therapy drugs worsen the burden of disease in the Region. Therefore, increasing public and professional knowledge and awareness is a major necessity.

In October 2021, AHF convened a meeting of Latin American experts on BRAF Melanoma via Zoom to develop recommendations for increasing the adoption of targeted treatments in the Region. The manuscript entitled “Addressing the Unmet Needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective” has been published at Frontiers. Click to read full article.